Abstract: A vaccine strain OU5758 is provided which includes an attenuated immunogenic plasmidless Salmonella enterica serovar-Typhimurium strain OU5046 harboring a recombinant plasmid pOU1500 for immunizing a chicken against leucocytozoonosis. The strain OU5046 is adapted to remain substantially avirulent, survive in vivo for at least a number of days, colonize within the chicken's liver, spleen, ovaries, or other internal organs, and express foreign antigens. The recombinant plasmid pOU1500 contains a gene encoding the circumsporozoite protein of the sporozoite of the chicken leucocytozoonosis parasite Leucocytozoon caulleryi. The vaccine strain OU5758 containing pOU1500 is capable of expressing circumsporozoite protein of L. caulleryi sporozoite, inducing anti-L. caulleryi immunity in chickens when ingested, reducing the frequency and severity of the disease's occurrence, and thereby enabling the chicken to maintain its normal egg production.

Abstract: V. cholerae vaccine strains which have a soft agar penetration-defective phenotype and methods for making such strains are described. Also described are methods for identifying new genes involved in V. cholerae motility and the cloning, identification, and sequencing of V. cholerae motB and fliC genes.

Abstract: The invention relates to novel Haemophilus adhesion proteins, nucleic acids, and antibodies.

Abstract: Methods for obtaining surface expression of a desired protein or polypeptide in Gram-positive host organisms are provided. In addition, vectors useful in such methods as well as Gram-positive host organisms transformed with such vectors are disclosed.

Abstract: Purified and isolated nucleic acid molecules are provided which encode lactoferrin receptor proteins of Moraxella, such as M. catarrhalis, or a fragment or an analog of the lactoferrin receptor protein. The nucleic acid sequence may be used to produce recombinant lactoferrin receptor proteins Lbp1, Lbp2 and ORF3 of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection.

Abstract: The invention relates to a hyperblebbing strain of Neisseria gonorrhoeae which produces large amounts of blebs useful for production of blebosomes containing antigens for use as a vaccine delivery vehicle or as a diagnostic reagent. The invention also relates to a method for producing high levels of a desired protein in purified form using the hyperblebbing strain of N. gonorrhoeae, and to a vaccine delivery systems containing the blebosomes expressing the desired antigen.

Abstract: The present invention is directed to compositions and methods for the production for the prevention of disease due to P. haemolytica. In particular, the present invention provides P. haemolytica strains that produce inactive leukotoxin for vaccine and other uses. The present invention also provides compositions and methods for genetic manipulations in P. haemolytica.

Abstract: The isolation of the S. aureus fibrinogen binding protein gene is described and a minimal fibrinogen binding protein is identified. The protein finds use as a vaccine or a pharmaceutical composition for application to prevent infection, promotion of wound healing, blocking adherence to indwelling medical devices, or diagnosis of infection.

Abstract: Multimeric hybrid genes encoding the corresponding chimeric protein comprise a gene sequence coding for an antigenic region of a protein from a first pathogen linked to a gene sequence coding for an antigenic region of a protein from a second pathogen. The pathogens particularly are parainfluenza virus (PIV) and respiratory syncytial virus (RSV). A single recombinant immunogen is capable of protecting infants and similar susceptible individuals against diseases caused by both PIV and RSV.

Abstract: The invention provides fabF polypeptides and polynucleotides encoding fabF polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing fabF polypeptides to screen for antibacterial compounds.